Galapagos NV (NASDAQ:GLPG)‘s stock had its “overweight” rating reissued by investment analysts at Morgan Stanley in a research note issued to investors on Thursday. They currently have a $92.00 price objective on the biotechnology company’s stock. Morgan Stanley’s target price would suggest a potential upside of 13.50% from the stock’s previous close.

GLPG has been the subject of a number of other reports. Janney Montgomery Scott lowered shares of Galapagos NV from a “buy” rating to a “sell” rating in a report on Monday, April 24th. BidaskClub lowered shares of Galapagos NV from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Nomura cut their target price on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a report on Thursday, June 22nd. Stifel Nicolaus raised their target price on shares of Galapagos NV from $65.00 to $83.00 and gave the company a “hold” rating in a report on Monday, May 1st. Finally, Zacks Investment Research lowered shares of Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $93.14.

Shares of Galapagos NV (NASDAQ GLPG) traded up 10.78% during midday trading on Thursday, hitting $81.06. 2,828,819 shares of the stock were exchanged. Galapagos NV has a 1-year low of $52.50 and a 1-year high of $94.88. The firm has a 50-day moving average of $77.54 and a 200-day moving average of $79.01. The company’s market capitalization is $4.12 billion.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/morgan-stanley-reiterates-overweight-rating-for-galapagos-nv-glpg/1470953.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new position in Galapagos NV during the first quarter valued at approximately $161,000. Acadian Asset Management LLC purchased a new position in Galapagos NV during the second quarter valued at approximately $166,000. Bank of Montreal Can raised its position in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares during the last quarter. Pacad Investment Ltd. purchased a new position in Galapagos NV during the second quarter valued at approximately $168,000. Finally, Cim Investment Mangement Inc. purchased a new position in Galapagos NV during the first quarter valued at approximately $203,000. 19.99% of the stock is owned by institutional investors.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.